Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929890 | 0.77 | TAAR1 (0.52) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL52147 | 0.76 | — | — | |
| SCHEMBL30084583 | 0.76 | — | — | |
| SCHEMBL5486477 | 0.76 | TAAR1 (0.50) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL27955213 | 0.76 | IDO1 (0.64) | TAAR1IDO1ACHEMAOBMAOA | |
| SCHEMBL29596752 | 0.75 | TAAR1 (0.74) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL1263547 | 0.75 | TAAR1 (0.60) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL29459538 | 0.75 | TAAR1 (0.60) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL8096473 | 0.75 | TAAR1 (0.74) | TAAR1IDO1ACHEMAOBHRH3 | |
| SCHEMBL30000562 | 0.75 | TAAR1 (0.60) | TAAR1IDO1ACHEMAOBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-106999479-B | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | 米伦纽姆医药公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3517112-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2016004136-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | DUFFEY MATTHEW O (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914586-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Pfizer Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014068527-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2007735-B1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-2007735-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | Glaxo Group Limited (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20080039444-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007122156-A9 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007122156-A1 | 2-SUBSTITUTED 4-BENZYLPHTHALAZINONE DERIVATIVES AS HISTAMINE H1 AND H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | TAAR1 4137/4885IDO1 715/4885ACHE 2295/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | TAAR1 4340/4885IDO1 2009/4885ACHE 39/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | TAAR1 3902/4885IDO1 697/4885ACHE 2447/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | TAAR1 3902/4885IDO1 697/4885ACHE 2447/4885 |
| US-20080039444-A1 | COMPOUNDS | CMA1, MRGPRX2, HRH2 | TAAR1 699/4885IDO1 171/4885ACHE 1108/4885 |
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | TAAR1 1048/4885IDO1 116/4885ACHE 3577/4885 |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | TAAR1 4340/4885IDO1 2009/4885ACHE 39/4885 |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | TAAR1 4340/4885IDO1 2009/4885ACHE 39/4885 |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | TAAR1 4340/4885IDO1 2009/4885ACHE 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.